Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling
Cancer Cell · 2025-11 · 43 (11) · 2034-2050.e11
DOI: 10.1016/j.ccell.2025.05.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2025-11. Verfasst von Iva Nikolic und 21 weiteren Autor:innen. Beteiligte Einrichtung: oNKo-innate Pty Ltd., Moonee Ponds, VIC 3039, Australia. Hauptthemen laut MEDLINE: Killer Cells, Natural, Receptors, Interleukin-15, Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Institute of Neurological Disorders and Stroke, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
Interleukin-15 receptor (IL-15R) agonists induce anti-tumor immunity in pre-clinical models. However, dose-limiting toxicity has hampered their clinical development. We performed genome-wide CRISPR screens to reveal the complete IL-15R signaling mechanism in natural killer (NK) cells and discovered that ubiquitin-dependent IL-15R degradation is the dominant mechanism restraining IL-15R signaling. Key hits included the NEDD8 E2-conjugating enzyme UBE2F, the ubiquitin E3-ligase ARIH2, and Cullin-5 RING E3 ligase (CRL5) members. We found that UBE2F was required for neddylation and activation of CUL5, whereas ARIH2 contributed to CRL5-mediated IL-15RB degradation. Ablation of ARIH2 or UBE2F increased IL-15RB surface expression and enhanced signaling, resulting in proinflammatory cytokine production and augmented natural and CAR-mediated cytotoxicity. In mice lacking Arih2, Rnf7, or Ube2f, we observed that the IL-15R hyperresponsive NK cells exhibited superior in vivo anti-tumor immunity against primary and disseminated metastatic tumors. Thus, we have identified the enzymes UBE2F and ARIH2 as tractable immunotherapy drug targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- oNKo-innate Pty Ltd., Moonee Ponds, VIC 3039, Australia.
- Biomedicine Discovery Institute and the Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.
- Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China.
- oNKo-innate Pty Ltd., Moonee Ponds, VIC 3039, Australia. Electronic address: jai@onko-innate.com.
- oNKo-innate Pty Ltd., Moonee Ponds, VIC 3039, Australia; Biomedicine Discovery Institute and the Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia. Electronic address: nic…
Förderung
- National Institute of Neurological Disorders and Stroke
- National Institutes of Health
- National Cancer Institute
- National Institute on Drug Abuse
- National Institute of Mental Health
- National Human Genome Research Institute
- University of Melbourne
- National Heart, Lung, and Blood Institute
Zitieren
APA
Nikolic, I., Cursons, J., Shields, B., Chappaz, S., Sudholz, H., Meng, X., Constantinescu, P., Vijayakumaran, R., D'Angelo, M., Foroutan, M., Ladd, D., Veldman, M., Glab, J., Procter, T., Park, H. Y., Contet, J., Deuss, F., Wong, K., Sun, Y., …, & Huntington, N. D. (2025). Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling. Cancer Cell, 43(11), 2034-2050.e11. https://doi.org/10.1016/j.ccell.2025.05.011
Vancouver
Nikolic I, Cursons J, Shields B, Chappaz S, Sudholz H, Meng X, et al. Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling. Cancer Cell. 2025;43(11):2034-2050.e11. doi:10.1016/j.ccell.2025.05.011
BibTeX
@article{Nikolic2025,
author = {Nikolic, Iva and Cursons, Joseph and Shields, Benjamin and Chappaz, Stephane and Sudholz, Harrison and Meng, Xiangpeng and Constantinescu, Patrick and Vijayakumaran, Reshma and D'Angelo, Michael and Foroutan, Momeneh and Ladd, David and Veldman, Matthew and Glab, Jason and Procter, Tahlia and Park, Hae-Young and Contet, Julian and Deuss, Felix and Wong, Kahlia and Sun, Yi and Berry, Richard and Rautela, Jai and Huntington, Nicholas D},
title = {Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling},
journal = {Cancer Cell},
year = {2025},
volume = {43},
number = {11},
pages = {2034--2050.e11},
doi = {10.1016/j.ccell.2025.05.011}
}
EUVIMED